Intellia Therapeutics, Inc.

Case Overview
48 Days Left to Seek Lead Plaintiff
Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 04/14/2025 |
Status: | Status: Investigating |
Company Name: | Company Name: Intellia Therapeutics, Inc. |
Court: | Court: District of Massachusetts |
Case Number: | Case Number: 1:25cv10353 |
Class Period: | Class Period: 07/30/2024 - 01/08/2025 |
Ticker: | Ticker: NTLA |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of Massachusetts on behalf of those who acquired Intellia Therapeutics, Inc. (“Intellia” or the “Company”) (NASDAQ:NTLA) securities during the period from July 30, 2024, through January 8, 2025 (“the Class Period”). Investors have until April 14, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.
On January 9, 2025, Intellia published a press release announcing the Company’s reorganization. In pertinent part, Intellia disclosed that it would be halting all NTLA-3001 research and studies and that the Company would be reducing its workforce by 27% in 2025. Specifically, the Company announced that management decided to focus Intellia’s resources on other pharmaceutical development and would be implementing cost savings in the form of a major reduction in force. On this news, the price of Intellia shares declined by $1.82 per share, from $12.02 per share on January 8, 2025, to close at $10.20 on January 10, 2025.
The complaint alleges that defendants, throughout the Class Period, failed to disclose inter alia that the demand for viral-based editing was rapidly dwindling as non-viral delivery methods became a main target of the scientific community due to their cost-effectiveness and more efficient development, thus making NTLA-3001 an inefficient program for Intellia to maintain.
On January 9, 2025, Intellia published a press release announcing the Company’s reorganization. In pertinent part, Intellia disclosed that it would be halting all NTLA-3001 research and studies and that the Company would be reducing its workforce by 27% in 2025. Specifically, the Company announced that management decided to focus Intellia’s resources on other pharmaceutical development and would be implementing cost savings in the form of a major reduction in force. On this news, the price of Intellia shares declined by $1.82 per share, from $12.02 per share on January 8, 2025, to close at $10.20 on January 10, 2025.
The complaint alleges that defendants, throughout the Class Period, failed to disclose inter alia that the demand for viral-based editing was rapidly dwindling as non-viral delivery methods became a main target of the scientific community due to their cost-effectiveness and more efficient development, thus making NTLA-3001 an inefficient program for Intellia to maintain.